# AR+/ER+ Breast Cancer The **AR+/ER+** pattern sits inside **ER-positive, HER2-negative** breast cancer. It matters most when AR looks biologically important, not just incidentally positive. That often means **high AR expression**, lower or moderate ER dominance, or **apocrine differentiation**. ### Jump menu * [Understanding your receptor profile](#understanding-your-receptor-profile) * [The pleomorphic lobular and apocrine subtype](#the-pleomorphic-lobular-and-apocrine-subtype) * [How the androgen receptor can act as a tumour suppressor in ER-positive disease](#how-the-androgen-receptor-can-act-as-a-tumour-suppressor-in-er-positive-disease) * [The two opposite treatment strategies](#the-two-opposite-treatment-strategies) * [Enobosarm: what it is and what the evidence shows](#enobosarm-what-it-is-and-what-the-evidence-shows) * [The bacterial microbiome connection](#the-bacterial-microbiome-connection) * [Monitoring for resistance: realistic markers for patients](#monitoring-for-resistance-realistic-markers-for-patients) * [Integrative support considerations](#integrative-support-considerations) * [Key questions for your oncologist](#key-questions-for-your-oncologist) * [Master reference list](#master-reference-list) * [Androgen modulation for other breast-cancer subtypes](#androgen-modulation-for-other-breast-cancer-subtypes) ### Understanding your receptor profile Most hormone-receptor discussions centre on estrogen. That can miss an important second receptor. That receptor is the **androgen receptor**, or **AR**. Around **90% of ER-positive breast cancers** also express AR. The important question is not simple AR positivity. The real question is whether AR is **functionally dominant**. In some ER-positive tumours, strong AR signalling may partly **restrain ER-driven growth**. That is why this subgroup deserves its own treatment logic. {% hint style="info" %} AR+/ER+ is not a separate formal subtype in the same way as HER2-positive or triple-negative. It is a useful clinical shorthand for a subgroup of ER-positive disease where AR may be biologically important. {% endhint %} ### The pleomorphic lobular and apocrine subtype This topic is especially relevant in tumours with **apocrine differentiation**. That includes rare settings such as **invasive pleomorphic lobular carcinoma with apocrine differentiation**. These tumours often show very strong AR expression. The pathology may also reflect an androgen-led biology. Markers worth noticing include: * **AR staining level** * **GCDFP-15** * **FOXA1** * apocrine morphology on the pathology report When these features cluster together, AR is more likely to matter biologically. *** ### How the androgen receptor can act as a tumour suppressor in ER-positive disease This is the key concept. AR and ER both depend on transcriptional helper proteins. Two important ones are **p300** and **SRC-3**. When AR is strongly activated in the right context: * AR can pull these coactivators away from ER * ER loses some ability to drive growth-promoting genes * ER can be displaced from some of its DNA binding sites * proliferation markers like **Ki67** may fall * tumour growth may slow This is why some researchers now describe AR as a **tumour suppressor** in part of ER-positive disease. The stronger the AR expression, the more plausible this effect becomes. That is one reason why **AR staining level** matters so much in this discussion. ### The two opposite treatment strategies This is the main practical fork. AR-targeted therapy can mean two very different things. #### AR antagonists Examples include **enzalutamide** and **bicalutamide**. These block AR signalling. That approach makes the most sense in **AR-driven, ER-negative** disease. It is most relevant in the **luminal androgen receptor** form of triple-negative breast cancer. #### AR agonists The main drug here is **enobosarm**. This activates AR instead of blocking it. That is the more biologically coherent approach when: * the tumour is **ER-positive** * AR is strongly expressed * the goal is to let AR suppress ER output The key idea is simple. The same receptor may need **blocking** in one subtype and **activating** in another. That is why AR antagonists and agonists are not interchangeable. *** ### Enobosarm: what it is and what the evidence shows Enobosarm is a **selective androgen receptor modulator**. It is also called **ostarine** or **GTx-024**. It is designed to activate AR with more tissue selectivity than standard androgen exposure. #### What the clinical data suggest A Phase II trial studied enobosarm in **AR-positive, ER-positive, HER2-negative advanced breast cancer**. The study reported: * measurable anti-tumour activity * better benefit when AR expression was higher * acceptable tolerability in the study setting * a strong separation between **high-AR** and **low-AR** tumours The most important signal was biomarker-driven. Patients with higher AR staining did much better than those with lower staining. That supports a **selection strategy**, not broad use. #### Why this is still early Enobosarm is still in the **investigational** clinical trial stage in breast cancer. It is not standard of care. It should be discussed through: * a clinical trial * a molecular tumour board * or a clinician-led access pathway where available *** ### The bacterial microbiome connection This part of the story is interesting, but less settled. Emerging papers suggest that gut and tumour microbiota may influence hormone handling, immune tone, and treatment response. Several ideas are being explored: * some gut bacteria may alter estrogen and androgen metabolism * beta-glucuronidase activity may reactivate hormone metabolites * **Fusobacterium nucleatum** may contribute to more aggressive breast-cancer behaviour * oral and periodontal health may matter more than once assumed This does **not** mean microbiome theories should drive treatment by themselves. It does mean microbiome and oral-health issues are worth taking seriously. The most defensible takeaways are practical ones: * address periodontal disease * investigate chronic dental infection properly * keep microbiome claims evidence-aware * treat more specific intervention claims with caution *** ### Monitoring for resistance: realistic markers for patients If AR-targeted logic is being discussed, resistance planning matters from the start. One emerging concern is a possible switch toward **JAK/STAT signalling** with prolonged AR activation. This remains an evolving research area. It is not yet a routine clinical rule. Still, it gives a useful framework for what to watch. #### Blood-based discussion points Markers worth asking about can include: * **IL-6** as a direct upstream inflammatory signal relevant to JAK/STAT * **CRP** as a crude downstream inflammatory marker * **ctDNA** to look for evolving resistance patterns if metastatic monitoring is already being considered #### If progression leads to re-biopsy These changes may matter: * rising **Ki67** * falling ER expression * loss of apocrine or luminal markers such as **GCDFP-15** or **FOXA1** * more aggressive histology or lineage shift * tissue evidence of **pSTAT3** if specifically requested The point is not to over-test. The point is to have a resistance plan before a promising strategy starts to fail. *** ### Integrative support considerations: * reviewing **oral health** and periodontal status * considering whether chronic dental infection needs better imaging or specialist review * keeping gut health, bowel function, and microbiome diversity in view during endocrine therapy * asking whether a **baseline IL-6** level is worth adding for context * using stool or microbiome testing cautiously, as supportive rather than decisive data The goal here is to tighten the broader terrain around treatment. It is not to replace pathology, imaging, or systemic oncology decisions. *** ### L. reuteri yoghurt as an oral-microbiome intervention A more specific supportive idea is worth considering. **Limosilactobacillus reuteri** is among the better-studied probiotic species for oral-pathogen displacement. The main interest here is its possible effect against **Fusobacterium nucleatum**. The proposed mechanisms are multi-layered: * **Physical coaggregation:** *L. reuteri* can bind directly to *F. nucleatum* and help pull it out of the biofilm community * **Competitive exclusion:** it can occupy oral adhesion sites and gradually displace pathogenic species * **Reuterin production:** it produces antimicrobial compounds that may work against Gram-negative anaerobes * **Biofilm disruption:** it may interfere with the acid-tolerance and persistence programs that help oral pathogens rebuild biofilm The overall logic is ecological, not drug-like. It is about shifting the oral microbial balance over time. That means consistency matters more than single doses. **If this is discussed with the care team, the main practical points are:** * **oral delivery matters most** * lozenges or slow oral exposure make more sense than simply swallowing capsules * repeated exposure through the day is more logical than one isolated dose * a **two-week trial window** is a reasonable minimum for looking for a shift in oral ecology A practical model is **three-times-daily** oral exposure through lozenge or yoghurt-rinse style use. That is a plausible practical model for an oral-biofilm goal. It should still be framed as a supportive strategy, not a proven oncology intervention. #### L. Reuteri in Oncology Guide **For more detailed strain, preparation, and safety notes, see the companion guide:** [**L. Reuteri in Oncology: A Deep Dive for Cancer Patients**](https://docs.google.com/document/d/e/2PACX-1vSr97oDRqgU1yiRYMkSaUodWA6c2PX9gTXpeyLCAEREUdLg7iPltrzvDzn_XZLaLuhDXpB7DxRjg_Tf/pub) #### Dental-source caution This question becomes more relevant when there is: * a history of **root canal treatment** * chronic gum disease * unexplained dental symptoms * concern for a persistent oral anaerobic reservoir If there is genuine concern about chronic dental infection, proper dental review matters more than probiotics alone. That may include: * targeted dental assessment * **CBCT** imaging when standard dental imaging has been unrevealing * review by a dentist who is comfortable thinking in oral-systemic terms If a periapical abscess or failed root canal is confirmed, source control matters. An oral probiotic cannot clear a sealed deep dental infection by itself. *** #### Triple-negative breast cancer This ER-positive logic does **not** carry across directly to triple-negative disease. In high-AR triple-negative breast cancer, the more relevant strategy is often **AR blockade**, not AR activation. #### HER2-positive disease There is no established clinical role for enobosarm in HER2-positive breast cancer. That includes patients previously treated with HER2-directed therapy. For now, AR activation in HER2-positive disease remains too uncertain to treat as a parallel strategy. *** ### Key questions for your oncologist 1. Is my tumour strongly **AR-positive**, or only weakly AR-positive? 2. Does my pathology suggest **apocrine differentiation** or another AR-dominant pattern? 3. In my case, does AR look more like a receptor to **activate** or **block**? 4. Would **enzalutamide** be biologically sensible here, or could it work against the goal? 5. Are there any suitable **enobosarm** studies or access pathways? 6. Should my pathology be reviewed for **GCDFP-15**, **FOXA1**, or repeat AR scoring? 7. Would **ctDNA** be useful for baseline or resistance monitoring? 8. If progression happens, should repeat biopsy be part of the next-step plan? 9. Should my case be reviewed by a **molecular tumour board** because of the receptor mix or rare histology? *** ### Master reference list 1. Hickey TE, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. *Nature Medicine*. 2021. DOI: 10.1038/s41591-020-01168-7 2. Asemota S, Effah J. A molecular switch from tumor suppressor to oncogene in ER+ breast cancer: role of androgen receptor, JAK-STAT, and lineage plasticity. *PNAS*. 2024. DOI: 10.1073/pnas.2406837121 3. Overmoyer B, et al. Activity and safety of enobosarm in androgen receptor-positive, estrogen receptor-positive, HER2-negative advanced breast cancer. *Lancet Oncology*. 2024. DOI: 10.1016/S1470-2045(24)00004-4 4. Gucalp A, et al. Phase II trial of bicalutamide in androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. *Clinical Cancer Research*. 2013. DOI: 10.1158/1078-0432.CCR-12-3327 5. Elebro K, et al. Relationship between androgen receptor and androgen receptor-related markers in breast carcinoma with apocrine differentiation. *Scientific Reports*. 2025. DOI: 10.1038/s41598-025-87403-y 6. Ricciardelli C, et al. Pharmacological targeting of androgen receptor elicits context-dependent effects in breast cancer. *Cancer Research*. 2023. DOI: 10.1158/0008-5472.CAN-22-1686 7. Arruza Ibarra A, et al. Arming androgen receptors to oppose oncogenic estrogen receptor activity. *npj Breast Cancer*. 2021. DOI: 10.1038/s41523-021-00295-7 8. Chu D, et al. Modulating the activity of androgen receptor for treating breast cancer. *Frontiers in Endocrinology*. 2022. PMC8717192 9. Terrisse S, et al. Impact of microbiota on breast cancer hormone therapy. *Cell Stress*. 2023. DOI: 10.15698/cst2023.03.279 10. Gur C, et al. Breast cancer colonization by *Fusobacterium nucleatum* accelerates tumor growth and metastatic progression. *Nature Communications*. 2020. DOI: 10.1038/s41467-020-16967-2 11. Shi L, et al. Endocrine-targeting therapies shift the breast microbiome to reduce tumour-promoting bacteria. *Cell Reports Medicine*. 2024. DOI: 10.1016/j.xcrm.2024.101815 12. Nejman D, et al. Interactions between the tumor microbiota and breast cancer. *Frontiers in Cellular and Infection Microbiology*. 2025. DOI: 10.3389/fcimb.2024.1499203 13. Shi L, et al. *Fusobacterium nucleatum* promotes metastasis of breast cancer via CXCL-10 pathway. *Frontiers in Oncology*. 2025. PMC12206713 14. Momen-Heravi F, Babic A. The role of oral *Fusobacterium nucleatum* in female breast cancer. *Frontiers in Microbiology*. 2022. PMID: 36466367 15. Pham VT, et al. *Limosilactobacillus reuteri* DSM 17938 inhibition of *Fusobacterium nucleatum* biofilm formation in vitro. 2024. PMC11750330 16. Teles F, et al. *Limosilactobacillus reuteri–Fusobacterium nucleatum* interactions and competitive exclusion. *Journal of Periodontal Research*. 2025. DOI: 10.1111/jre.70021 17. Guo R, et al. *Lactobacillus reuteri* biofilms inhibit pathogens and regulate host immunity. *Journal of Agricultural and Food Chemistry*. 2022. DOI: 10.1021/acs.jafc.2c02372 18. *Limosilactobacillus reuteri* inhibits the acid tolerance response in oral biofilm bacteria. 2023. PMC10319175 19. Fusobacterium in the microbiome: from health to disease across the body. *npj Biofilms and Microbiomes*. 2025. DOI: 10.1038/s41522-025-00838-z 20. Sharma D, et al. How bacteria promote breast cancer. *Cell Communication and Signaling* / Johns Hopkins reporting. 2026. --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/ar+-er+-breast-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.